Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12844824 | 0.84 | KMT2A (0.50) | GRM5GRM1KMT2ACYP3A4KDM4E | |
| SCHEMBL29685392 | 0.84 | KMT2A (0.50) | GRM5GRM1KMT2ACYP3A4KDM4E | |
| SCHEMBL18378772 | 0.79 | KMT2A (0.47) | KMT2AMPOCYP3A4ALDH1A1POLB | |
| SCHEMBL16963976 | 0.77 | TLR8 (0.46) | APLNRGRM5GRM1KMT2AKDM4E | |
| SCHEMBL6312157 | 0.76 | KMT2A (0.44) | KMT2AMPOCYP3A4KDM4ETSHR | |
| SCHEMBL7921177 | 0.75 | CA1 (0.52) | KMT2ACYP3A4KDM4EALDH1A1TSHR | |
| SCHEMBL19589424 | 0.73 | MPO (0.46) | APLNRGRM5KMT2AMPOCYP3A4 | |
| SCHEMBL25731715 | 0.73 | ACHE (0.46) | APLNRGRM5KMT2ACYP3A4KDM4E | |
| SCHEMBL16911976 | 0.73 | KMT2A (0.38) | APLNRGRM5GRM1KMT2AMPO | |
| SCHEMBL17194964 | 0.73 | KMT2A (0.42) | GRM5KMT2AMPOCYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663234-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | Pfizer Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050043300-A1 | Piperazine derivatives | PFIZER INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005016344-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043300-A1 | Piperazine derivatives | CD4, CCR5, RRP15 | APLNR 3351/4885GRM5 803/4885GRM1 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.